Synlogic Links Up With AbbVie For IBD Microbiome Therapies
This article was originally published in Scrip
Synlogic Inc., focused on the intersection of synthetic biology and microbiome therapeutics, signed its first partnership Feb. 10, agreeing to a multi-year collaboration with AbbVie Inc. to develop what it calls "synthetic biotic" therapies for Crohn's disease and ulcerative colitis.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
The synthetic biotics company is discontinuing development of SNYB1020, its first clinical-stage product, which failed to lower blood ammonia in cirrhosis patients.
Emerging Company Profile: Pioneering the development of a new class of living medicines that work in the microbiome, Synlogic completed a reverse merger earlier this year that took the company public.